Brief: OncoTherapy Science says result of phase I clinical trial of OTS103/104 (OCV-C02)
18/01/2017 08:19
Jan 18 (Reuters) - OncoTherapy Science Inc 4564.T :
* Says Phase 1 trial of OCV-C02, a peptide vaccine for
metastatic colorectal cancer patients refractory
to all standard chemotherapies
* Says OCV-C02 at 0.3 to 6 mg/body exhibited a safe and well
tolerated profile, and showed immunological responses in mCRC
pts refractory to all standard chemotherapies
Source text in Japanese: https://goo.gl/A9hc83
Further company Coverage: 4564.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: qiujing.li.thomsonreuters.com@reuters.net))